ArticleFrontiers in endocrinology2026
Correlation between serum prolactin and the systemic immune-inflammation index in diabetic kidney disease: a cross-sectional study.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Prolactin (PRL) is increasingly recognized as a pleiotropic hormone with potent immunoregulatory properties; however, its involvement in systemic inflammation among diabetic kidney disease (DKD) patients has not been defined. This study aimed to investigate the potential association between serum PRL levels and micro-inflammation in patients with DKD. Methods: In this cross-sectional investigation, 994 patients with type 2 diabetes mellitus (T2DM)-associated DKD were enrolled. Multivariable linear mixed-effects models were used to quantify the relationship between serum PRL and the systemic immune-inflammation index (SII) and other clinical parameters. Restricted cubic spline (RCS) analyses were fitted to test for non-linearity and stratified and sensitivity analyses were performed to assess robustness. Results: The median serum PRL level was 344.40 mIU/L (interquartile range: 258.80-463.10). After multivariable adjustment, serum PRL were positively associated with white blood cell count, neutrophil count, serum ferritin, serum phosphorus and intact parathyroid hormone (iPTH) levels, and inversely associated with serum albumin. For every 100 mIU/L increase in serum PRL, the SII increased by an average of 7.10 units (95% CI: 3.13 to 11.07; Conclusion: In patients with DKD, serum PRL exhibits an independent, nonlinear association with SII, characterized by a threshold around 282.85 mIU/L. This finding suggests that PRL may be linked to the dysregulated immune-inflammation axis in DKD, warranting further mechanistic and longitudinal investigation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.